Auszug
Entsprechend den derzeitigen Therapieempfehlungen konzentrieren sich 51% der Antiepileptikaverordnungen auf die beiden Standardtherapeutika Carbamazepin und Valproinsäure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (2006): Arzneiverordnungen. 21. Aufl., Deutscher Ärzte-Verlag, Köln.
Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. for the Gabapentin Diabetic Neuropathy Study Group (1998): Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280: 1831–1836.
Ben-Menachem E, Scheepers B, Stodieck S (2003): Epilepsy: from consensus to daily practice. Acta Neurol Scand 108(Suppl 180): 5–15.
Beydoun A (1997): Monotherapy trials of new antiepileptic drugs. Epilepsia 38(Suppl 9): S21–S31.
Beydoun A (1999): Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 40(Suppl 6): S13–S16.
Brodie MJ (2004): Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45Suppl 6: 19–27.
Charatan F (2002): Doctor sues company over unethical marketing. Brit Med J 324: 1234.
Dooley M, Plosker GL (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871–893.
Feely M (1999): Drug treatment of epilepsy. Brit Med J 318: 106–109.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee (2004): Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45: 401–409.
Goa KL, Ross SR, Chrisp P (1993): Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152–176.
Groß-Selbeck G (1995): Treatment of „benign“ partial epilepsies of childhood, including atypical forms. Neuropediatrics 26: 45–50.
Heaney DC, Shorvon SD, Sander JW (1998): An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 39(Suppl 3): S19–S25.
Hitiris N, Brodie MJ (2006): Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 19: 175–180.
Hufnagel A, Noachtar S (1998): Epilepsien und ihre medikamentöse Behandlung. In: Brandt T, Dichgans J, Diener HC (Hrsg): Therapie und Verlauf neurologischer Erkrankungen. 3. Aufl., Kohlhammer, Stuttgart, Berlin, Köln, S. 179–203.
Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B (2000): Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 106: 838–842.
Jette NJ, Marson AG, Kadir ZA, Hutton JL (2000): Topiramate for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2: CD001417.
Kwan P, Brodie MJ (2004): Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45: 1141–1149.
LaRoche SM, Helmers SL (2004): The new antiepileptic drugs: scientific review. JAMA 291: 605–614.
McCorry D, Chadwick D, Marson A (2004): Current drug treatment of epilepsy in adults. Lancet Neurol 3: 729–735.
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999): Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159: 1931–1937.
National Institute for Clinical Excellence (NICE) (2004a): The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20, issue date: October 2004. Internet: www.nice.org.uk/page.aspx?o=CG020NICEguideline
National Institute for Clinical Excellence (NICE) (2004b): Newer drugs for epilepsy in adults. Technology Appraisal Guidance 76. Internet: www.nice.org.uk/page.aspx?o=ta076guidance
Scottish Intercollegiate Guidelines Network (2003): Diagnosis and management of epilepsy in adults. A national clinical guideline. April 2003. www.sign.ac.uk/pdf/sign70.pdf
Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O’Meara S, Sculpher M, Drummond M, Forbes C (2005): Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 9: 1–157, iii–iv.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2007). Antiepileptika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-34370-7_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34369-1
Online ISBN: 978-3-540-34370-7
eBook Packages: Medicine (German Language)